Aprea Therapeutics, Inc. Operating Lease, Expense
Aprea Therapeutics, Inc. (APRE) reported Operating Lease, Expense of $23.61 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- Aprea Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $23.61K, a 1.16% increase year-over-year.
- Aprea Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $23.64K, a 1.79% increase year-over-year.
- Aprea Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $23.38K, a 16.90% increase year-over-year.
- Aprea Therapeutics, Inc. operating lease, expense for the quarter ending 2025-06-30 was $23.34K, a 16.70% increase year-over-year.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $23.61K 10-Q · filed 2026-08-12 | $47.25K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $23.64K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $23.38K 10-Q · filed 2025-11-12 | $46.71K derived: sum of 2 quarters · filed 2026-08-12 | $69.94K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $23.34K 10-Q · filed 2026-08-12 | $46.56K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $23.22K 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | $20.00K 10-Q · filed 2025-11-12 | $39.99K derived: sum of 2 quarters · filed 2025-11-12 | $59.99K 10-Q · filed 2025-11-12 |
| 2024-06-30 | $20.00K 10-Q · filed 2025-08-12 | $39.99K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-14 | ||
| 2023-09-30 | $20.00K 10-Q · filed 2024-11-07 | $39.99K derived: sum of 2 quarters · filed 2024-11-07 | $59.99K 10-Q · filed 2024-11-07 |
| 2023-06-30 | $20.00K 10-Q · filed 2024-08-12 | $39.99K 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $20.00K 10-Q · filed 2024-05-14 | ||
| 2022-09-30 | $77.02K 10-Q · filed 2023-11-09 | $161.92K derived: sum of 2 quarters · filed 2023-11-09 | $236.74K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $84.90K 10-Q · filed 2023-08-10 | $159.72K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $74.82K 10-Q · filed 2023-05-15 | ||
| 2021-09-30 | $81.66K 10-Q · filed 2022-11-09 | $166.06K derived: sum of 2 quarters · filed 2022-11-09 | $257.74K 10-Q · filed 2022-11-09 |
| 2021-06-30 | $84.40K 10-Q · filed 2022-08-12 | $176.09K 10-Q · filed 2022-08-12 | |
| 2021-03-31 | $91.69K 10-Q · filed 2022-05-16 | ||
| 2020-09-30 | $84.48K 10-Q · filed 2021-11-08 | $161.98K derived: sum of 2 quarters · filed 2021-11-08 | $241.81K 10-Q · filed 2021-11-08 |
| 2020-06-30 | $77.50K 10-Q · filed 2021-08-12 | $157.32K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |